Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease
(2026) In Alzheimer's Research & Therapy 18(1).- Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous and often complicated by the presence of multiple co-pathologies, which can overlap with features of other neurodegenerative disorders, underscoring the need for tools to aid accurate and timely diagnosis. Biomarkers for AD span multiple modalities and are being increasingly used in clinical settings to aid diagnosis, monitor disease progression, and assess eligibility and response to disease-modifying therapies. Here, we provide an overview of current clinical applications of fluid, imaging, and digital biomarkers for AD. We also discuss biomarkers under development and challenges... (More)
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous and often complicated by the presence of multiple co-pathologies, which can overlap with features of other neurodegenerative disorders, underscoring the need for tools to aid accurate and timely diagnosis. Biomarkers for AD span multiple modalities and are being increasingly used in clinical settings to aid diagnosis, monitor disease progression, and assess eligibility and response to disease-modifying therapies. Here, we provide an overview of current clinical applications of fluid, imaging, and digital biomarkers for AD. We also discuss biomarkers under development and challenges associated with the implementation of these modalities in clinical settings.
(Less)
- author
- organization
- publishing date
- 2026-01-09
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Alzheimer's Research & Therapy
- volume
- 18
- issue
- 1
- article number
- 14
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:41508141
- ISSN
- 1758-9193
- DOI
- 10.1186/s13195-025-01921-5
- language
- English
- LU publication?
- yes
- id
- 74ee0ca7-56d8-458d-b656-b65660b7b364
- date added to LUP
- 2026-01-20 16:38:31
- date last changed
- 2026-01-20 16:39:44
@article{74ee0ca7-56d8-458d-b656-b65660b7b364,
abstract = {{<p>Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous and often complicated by the presence of multiple co-pathologies, which can overlap with features of other neurodegenerative disorders, underscoring the need for tools to aid accurate and timely diagnosis. Biomarkers for AD span multiple modalities and are being increasingly used in clinical settings to aid diagnosis, monitor disease progression, and assess eligibility and response to disease-modifying therapies. Here, we provide an overview of current clinical applications of fluid, imaging, and digital biomarkers for AD. We also discuss biomarkers under development and challenges associated with the implementation of these modalities in clinical settings.</p>}},
author = {{Bacci, Julia R and Karagianni, Stamatia and Alexopoulou, Zampeta-Sofia and Moukaled, Shirine and Tato-Fernández, Claudia and Arunachalam, Prithvi and Aslanyan, Aram and Aye, Sandar and Rocha, Ana Sabsil Lopez and Crugel, Monica and Fawad, Ayesha and Sogorb-Esteve, Aitana and Schöll, Michael and König, Alexandra and Paterson, Ross W}},
issn = {{1758-9193}},
language = {{eng}},
month = {{01}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{Alzheimer's Research & Therapy}},
title = {{Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease}},
url = {{http://dx.doi.org/10.1186/s13195-025-01921-5}},
doi = {{10.1186/s13195-025-01921-5}},
volume = {{18}},
year = {{2026}},
}
